Figure S3 from Inhibition of <i>MCL-1</i> and MEK Overcomes MEK Inhibitor Resistance in Triple-Negative and Inflammatory Breast Cancers by Mohd Mughees (15998547)

Figure S4 from Inhibition of <i>MCL-1</i> and MEK Overcomes MEK Inhibitor Resistance in Triple-Negative and Inflammatory Breast Cancers by Mohd Mughees (15998547)

Chart illustrates the treated groups (BM-MSC1, BM-MSC2, AD-MSC1, AD-MSC2) increasing in cell viability over replicates, while the untreated groups (Un-BM1, Un-BM2, Un-AD1, Un-AD2)... by Alani Mohanad Khalid Ahmed (22693496)

Major research and development steps required for development of a therapeutic product from HPE/constituent AMPPs. by Kate Summer (20592229)

Supporting data for “<b>Human Lipocalin-2 Variants: Therapeutic Evaluations</b>” by Haoyun Li (9151469)

“…</p><p dir="ltr">These findings highlight the complex interplay between lipocalin-2 variants, NETs, and inflammation, suggesting that targeting lipocalin-2 variant C87A may represent a novel therapeutic strategy to mitigate chronic inflammatory conditions and their cardiovascular complications. …”

FigureS4 from Early Evaluation of Circulating Tumor DNA as Marker of Therapeutic Efficacy in Metastatic Colorectal Cancer Patients (PLACOL Study) by Fanny Garlan (3153183)

Data Supplement from Centmitor-1, a Novel Acridinyl-Acetohydrazide, Possesses Similar Molecular Interaction Field and Antimitotic Cellular Phenotype as Rigosertib, ON 01910.Na by Jenni H.E. Mäki-Jouppila (15067084)

Data Supplement from Centmitor-1, a Novel Acridinyl-Acetohydrazide, Possesses Similar Molecular Interaction Field and Antimitotic Cellular Phenotype as Rigosertib, ON 01910.Na by Jenni H.E. Mäki-Jouppila (15067084)

The main research content of the article. by Jingxuan Wang (435196)

Subjects:

Supplementary Figure 1 from Delineating the mTOR Kinase Pathway Using a Dual TORC1/2 Inhibitor, AZD8055, in Multiple Myeloma by Diana Cirstea (48960)

FigureS3 from Early Evaluation of Circulating Tumor DNA as Marker of Therapeutic Efficacy in Metastatic Colorectal Cancer Patients (PLACOL Study) by Fanny Garlan (3153183)

Structural alterations in hydrogen bond networks of the TP53 protein caused by mutations G266E (A-B), G105C (C-D), R273C (E-F), R280G (G-H), and Q136P (I-J). by Ashraf Attia Mahmoud (21262201)

Subjects:

Proposed model and hypotheses (H). by Alessandro Carrera (15226859)

Subjects:

Overview of the methodology followed. by Alessandro Carrera (15226859)

Subjects:

Supplemental Figures 1-7 from Erlotinib Pretreatment Improves Photodynamic Therapy of Non–Small Cell Lung Carcinoma Xenografts via Multiple Mechanisms by Shannon M. Gallagher-Colombo (14918058)

Figure 5 from High-Purity CTC RNA Sequencing Identifies Prostate Cancer Lineage Phenotypes Prognostic for Clinical Outcomes by Marina N. Sharifi (21233542)

DataSheet2_Selective Serotonin Reuptake Inhibitor Pharmacokinetics During Pregnancy: Clinical and Research Implications.xlsx by Ethan A. Poweleit (12151800)

DataSheet1_Selective Serotonin Reuptake Inhibitor Pharmacokinetics During Pregnancy: Clinical and Research Implications.docx by Ethan A. Poweleit (12151800)

Concurrent mixed methods design diagram. by Esario IV Daguman (21474116)

Subjects:

The guiding map. by Esario IV Daguman (21474116)

Subjects: